On Friday, September 23, 2022, the advisory committee will hear an update on NDA for COPIKTRA (duvelisib) capsule, submitted by Secura Bio for use in the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least two prior therapies.
Back to All Events
Earlier Event: September 22
Oncologic Drug Advisory Committee
Later Event: October 6
Vaccines and Related Biological Products Advisory Committee (VRBPAC)